Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspiration Hlt Regulatory News (IHC)

Share Price Information for Inspiration Hlt (IHC)

Share Price is delayed by 15 minutes
Get Live Data
22.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (4.545%)
Market Cap: £20.17m
IHC Live PriceLast checked at - London Stock Exchange

Intraday Inspiration Hlt Share Chart

Full year trading update

12 Feb 2026 07:00

RNS Number : 6706S
Inspiration Healthcare Group PLC
12 February 2026
Β 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Β 

Full year trading update

Β 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering best-in-class, specialist neonatal intensive care medical devices, provides its unaudited trading update for year ended 31 January 2026 ("FY26").

Β 

Highlights

Β 

Β· Strong H2 trading performance, with revenue of Β£23.5 million, up 10.3% year-on-year (H2 FY25: Β£21.3 million)

Β· FY26 revenue growth of 24.0% to Β£47.5 million (FY25: Β£38.3 million)

Β· Adjusted EBITDA in line with current consensus market expectations1

Β· Good sales momentum expected to continue into FY27 with a solid pipeline of opportunities

Β· New multi-year purchasing agreement signed with one of the largest hospital networks in the United States

Β· Net debt reduced 39% to Β£5.1 million at 31 January 2026 (31 January 2025: Β£8.3 million)

Β 

Revenue for the year increased by approximately 24% to Β£47.5 million (FY25: Β£38.3 million), slightly ahead of consensus market expectations, following a strong H2 performance across the Group. Adjusted EBITDA is expected to be in line with market consensus, as a result of sales mix effects. Progress continues under the Group's 'Back to Basics' strategy, with stronger operational execution leading to an improved sales outlook, growing profits, positive cash flow and reducing net debt.

Β 

SLE, our global leader in neonatal ventilation, delivered a strong performance in H2 exceeding management expectations, following the re-alignment of the Group's branding. With local distributor managers now in place in Southeast Asia and Latin America, SLE is well positioned to re-establish its international position which will support the Group's growth strategy.

Β 

At the end of FY26, the Company announced a significant three-year purchasing agreement with one of the largest hospital networks in the United States, through its subsidiary in Florida, Airon Corporation ("Airon"). This agreement includes an initial order for 150 units for its Model A and Neo ventilators and accessories, representing a meaningful expansion to its installed base in the US. This contract establishes a high-quality, long-term revenue stream for Airon and directly supports Inspiration Healthcare's strategic objective of doubling Airon revenue within five years. In addition to initial equipment sales, the agreement includes expectations for ongoing consumables and service revenue, which has the potential to substantially increase the lifetime value of the partnership.

Β 

At 31 January 2026, the Group's net debt (excluding IFRS16 lease liabilities) was Β£5.1 million a reduction of 39% (Β£3.2 million) over the year with the Group achieving significant reductions in inventory and receivables under its 'Back to Basics' strategy.

Β 

1 Current consensus market expectations for FY26 revenue and adjusted EBITDA are Β£44.1 million and Β£2.8 million respectively.

Β 

Raffi Stepanian, CEO of Inspiration Healthcare, said: "FY26 represents a year of good progress for Inspiration Healthcare, with full year revenues increasing to Β£47.5 million and adjusted EBITDA expected to be in line with market expectations. We saw a strong performance across the Group, which combined with disciplined execution of our 'Back to Basics' strategy, has driven a return to growth in our international markets, improved profitability and reduced net debt.

Β 

"Our refreshed strategy with three business units: SLE for neonatal ventilation globally, Inspiration Healthcare as a medtech distribution channel in the UK and Ireland, and Airon as global leader in pneumatic ventilation is fully implemented. With increased focus on gaining share in Europe, increasing recurring revenues from consumables and service, we are taking important steps towards higher quality revenue streams complementing the revenue from capital sales. We ended the year with encouraging sales momentum and a robust pipeline, providing confidence within the team as we look ahead to FY27."

Β 

For further information, please contact:

Β 

Inspiration Healthcare Group plc

Tel: +44 (0)330 175 0000

Raffi Stepanian, Chief Executive Officer

Alan Olby, Chief Financial Officer

Panmure Liberum (Nominated Adviser & Broker)

Tel: +44 (0)20 3100 2000

Will Goode

Emma Earl

Mark Rogers

Β 

Cavendish Capital Markets (Joint Broker)

Tel: + 44 (0)20 7220 0500

Giles Balleny / Joe Smith

Nigel Birks

Harriet Ward

Β 

Walbrook PR Ltd (Media & IR)

Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com

Anna Dunphy

Mob: +44 (0) 7876 741 001

Rachel Broad

Mob: +44 (0) 7747 515 393

Β 

About Inspiration Healthcare

Β 

Inspiration Healthcare (AIM: IHC)Β designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

Β 

The Company has a broad portfolio of its own products andΒ complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

Β 

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy. In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

Β 

The Company operates in the UK from its world-class Manufacturing and Technology Centre in Croydon, South London and in the USA from its facility in Melbourne, Florida.

Β 

Further information on Inspiration Healthcare can be found atΒ www.inspirationhealthcaregroup.com

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTAKDBNFBKDNBD
Date   Source Headline
16th Jun 20267:00 amRNSFinal Results
2nd Jun 20267:01 amRNSNotice of Results
2nd Jun 20267:00 amRNSTransfer of Non-Core Products to Focus on Neonatal
14th Apr 20267:00 amRNSChange of Adviser
16th Mar 20269:33 amRNSHolding(s) in Company
16th Mar 20269:33 amRNSHolding(s) in Company
5th Mar 20267:00 amRNSUK neonatal division wins NHS framework agreement
26th Feb 20269:23 amRNSHolding(s) in Company
12th Feb 20267:00 amRNSFull year trading update
10th Feb 20269:05 amRNSHolding(s) in Company
3rd Feb 20267:00 amRNSAppointment of Joint Broker
2nd Feb 202611:01 amRNSHolding(s) in Company
28th Jan 20261:40 pmRNSHolding(s) in Company
28th Jan 20267:00 amRNSPurchasing agreement in the US
27th Jan 20269:46 amRNSHolding(s) in Company
26th Jan 202610:02 amRNSHolding(s) in Company
22nd Jan 20261:37 pmRNSHolding(s) in Company
26th Nov 20257:00 amRNSChange of auditor
16th Oct 20251:51 pmRNSHolding(s) in Company
7th Oct 20257:00 amRNSHalf-year Report
23rd Sep 20257:00 amRNSResults presentations for analysts and investors
19th Sep 20257:00 amRNSDirectorate Change
20th Aug 20257:00 amRNSTrading update and notice of results
24th Jul 20251:37 pmRNSResult of AGM
24th Jul 20257:00 amRNSAGM Statement
13th Jun 20259:16 amRNSPublication of AR, accounts & notice of AGM
6th Jun 20257:00 amRNSBoard Change
28th May 20257:00 amRNSUnaudited Preliminary results
23rd May 20257:00 amRNSNotice of Results
15th May 20255:01 pmRNSHolding(s) in Company
15th May 202510:06 amRNSHolding(s) in Company
1st Apr 202511:36 amRNSHolding(s) in Company
21st Mar 20252:49 pmRNSGrant of Options
12th Mar 20256:01 pmRNSHolding(s) in Company
12th Mar 20256:00 pmRNSDirector/PDMR Shareholding
24th Feb 20254:16 pmRNSDirector/PDMR Shareholding
21st Feb 20252:52 pmRNSDirector/PDMR Shareholding
18th Feb 20257:00 amRNSTrading update
10th Feb 20259:54 amRNSHolding(s) in Company
28th Jan 20257:00 amRNSDirectorate Change
14th Jan 20254:08 pmRNSHolding(s) in Company
12th Dec 20247:00 amRNSAppointment of Chief Executive Officer
14th Nov 20247:00 amRNSBoard Change
4th Nov 20247:00 amRNSGrant of Covenant Waiver and Covenant Reset
2nd Oct 20247:00 amRNSHalf-year Report
17th Sep 202412:26 pmRNSResult of AGM
3rd Sep 20247:00 amRNSTrading update for the six months to 31 July 2024
5th Aug 20243:41 pmRNSHolding(s) in Company
2nd Aug 20247:00 amRNSNominated adviser and broker
31st Jul 20243:29 pmRNSPublication of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.